Logo image of CSTL

CASTLE BIOSCIENCES INC (CSTL) Stock Fundamental Analysis

NASDAQ:CSTL - Nasdaq - US14843C1053 - Common Stock - Currency: USD

25.75  -0.4 (-1.53%)

After market: 25.75 0 (0%)

Fundamental Rating

5

Overall CSTL gets a fundamental rating of 5 out of 10. We evaluated CSTL against 108 industry peers in the Health Care Providers & Services industry. CSTL has a great financial health rating, but its profitability evaluates not so good. CSTL is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CSTL had positive earnings in the past year.
CSTL had a positive operating cash flow in the past year.
In the past 5 years CSTL reported 4 times negative net income.
In multiple years CSTL reported negative operating cash flow during the last 5 years.
CSTL Yearly Net Income VS EBIT VS OCF VS FCFCSTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M

1.2 Ratios

CSTL's Return On Assets of 1.18% is in line compared to the rest of the industry. CSTL outperforms 58.88% of its industry peers.
CSTL's Return On Equity of 1.38% is in line compared to the rest of the industry. CSTL outperforms 58.88% of its industry peers.
Industry RankSector Rank
ROA 1.18%
ROE 1.38%
ROIC N/A
ROA(3y)-11.48%
ROA(5y)-6.86%
ROE(3y)-13.03%
ROE(5y)-7.61%
ROIC(3y)N/A
ROIC(5y)N/A
CSTL Yearly ROA, ROE, ROICCSTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 50 -50 100 -100 -150

1.3 Margins

CSTL has a better Profit Margin (1.95%) than 65.42% of its industry peers.
The Gross Margin of CSTL (81.90%) is better than 93.46% of its industry peers.
CSTL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 1.95%
GM 81.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y0.71%
CSTL Yearly Profit, Operating, Gross MarginsCSTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

8

2. Health

2.1 Basic Checks

CSTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CSTL has been increased compared to 1 year ago.
Compared to 5 years ago, CSTL has more shares outstanding
Compared to 1 year ago, CSTL has an improved debt to assets ratio.
CSTL Yearly Shares OutstandingCSTL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CSTL Yearly Total Debt VS Total AssetsCSTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

CSTL has an Altman-Z score of 6.62. This indicates that CSTL is financially healthy and has little risk of bankruptcy at the moment.
CSTL has a Altman-Z score of 6.62. This is amongst the best in the industry. CSTL outperforms 91.59% of its industry peers.
CSTL has a debt to FCF ratio of 0.30. This is a very positive value and a sign of high solvency as it would only need 0.30 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.30, CSTL belongs to the best of the industry, outperforming 91.59% of the companies in the same industry.
CSTL has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.02, CSTL belongs to the best of the industry, outperforming 80.37% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.3
Altman-Z 6.62
ROIC/WACCN/A
WACC9.06%
CSTL Yearly LT Debt VS Equity VS FCFCSTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 7.78 indicates that CSTL has no problem at all paying its short term obligations.
With an excellent Current ratio value of 7.78, CSTL belongs to the best of the industry, outperforming 98.13% of the companies in the same industry.
CSTL has a Quick Ratio of 7.64. This indicates that CSTL is financially healthy and has no problem in meeting its short term obligations.
CSTL's Quick ratio of 7.64 is amongst the best of the industry. CSTL outperforms 98.13% of its industry peers.
Industry RankSector Rank
Current Ratio 7.78
Quick Ratio 7.64
CSTL Yearly Current Assets VS Current LiabilitesCSTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 107.04% over the past year.
Looking at the last year, CSTL shows a very strong growth in Revenue. The Revenue has grown by 62.43%.
The Revenue has been growing by 57.33% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)107.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130.77%
Revenue 1Y (TTM)62.43%
Revenue growth 3Y51.99%
Revenue growth 5Y57.33%
Sales Q2Q%39.5%

3.2 Future

The Earnings Per Share is expected to grow by 13.90% on average over the next years. This is quite good.
CSTL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.77% yearly.
EPS Next Y118.71%
EPS Next 2Y7.28%
EPS Next 3Y10.01%
EPS Next 5Y13.9%
Revenue Next Year55.38%
Revenue Next 2Y14.04%
Revenue Next 3Y12.7%
Revenue Next 5Y11.77%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CSTL Yearly Revenue VS EstimatesCSTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
CSTL Yearly EPS VS EstimatesCSTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 128.75 indicates a quite expensive valuation of CSTL.
Compared to the rest of the industry, the Price/Earnings ratio of CSTL is on the same level as its industry peers.
When comparing the Price/Earnings ratio of CSTL to the average of the S&P500 Index (29.63), we can say CSTL is valued expensively.
CSTL is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 128.75
Fwd PE N/A
CSTL Price Earnings VS Forward Price EarningsCSTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as CSTL.
Based on the Price/Free Cash Flow ratio, CSTL is valued a bit cheaper than the industry average as 71.96% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 20.88
EV/EBITDA 21.51
CSTL Per share dataCSTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

CSTL's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.08
PEG (5Y)N/A
EPS Next 2Y7.28%
EPS Next 3Y10.01%

More info and screens

0

5. Dividend

5.1 Amount

CSTL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CASTLE BIOSCIENCES INC

NASDAQ:CSTL (2/21/2025, 8:11:09 PM)

After market: 25.75 0 (0%)

25.75

-0.4 (-1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners95.85%
Inst Owner Change-89.21%
Ins Owners2.84%
Ins Owner Change0.47%
Market Cap721.26M
Analysts88
Price Target41.48 (61.09%)
Short Float %6.3%
Short Ratio4.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)218.11%
Min EPS beat(2)213.12%
Max EPS beat(2)223.11%
EPS beat(4)4
Avg EPS beat(4)147.84%
Min EPS beat(4)73.41%
Max EPS beat(4)223.11%
EPS beat(8)7
Avg EPS beat(8)83.83%
EPS beat(12)10
Avg EPS beat(12)65.88%
EPS beat(16)12
Avg EPS beat(16)48.63%
Revenue beat(2)2
Avg Revenue beat(2)14.17%
Min Revenue beat(2)5.33%
Max Revenue beat(2)23.01%
Revenue beat(4)4
Avg Revenue beat(4)12.9%
Min Revenue beat(4)5.33%
Max Revenue beat(4)23.01%
Revenue beat(8)8
Avg Revenue beat(8)12.31%
Revenue beat(12)12
Avg Revenue beat(12)10.93%
Revenue beat(16)16
Avg Revenue beat(16)11.93%
PT rev (1m)-2.14%
PT rev (3m)12.62%
EPS NQ rev (1m)229.82%
EPS NQ rev (3m)123.75%
EPS NY rev (1m)11.3%
EPS NY rev (3m)816.75%
Revenue NQ rev (1m)1.66%
Revenue NQ rev (3m)8.64%
Revenue NY rev (1m)0.28%
Revenue NY rev (3m)1.97%
Valuation
Industry RankSector Rank
PE 128.75
Fwd PE N/A
P/S 2.31
P/FCF 20.88
P/OCF 12.21
P/B 1.64
P/tB 2.18
EV/EBITDA 21.51
EPS(TTM)0.2
EY0.78%
EPS(NY)-1.83
Fwd EYN/A
FCF(TTM)1.23
FCFY4.79%
OCF(TTM)2.11
OCFY8.19%
SpS11.13
BVpS15.75
TBVpS11.8
PEG (NY)1.08
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.18%
ROE 1.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1.95%
GM 81.9%
FCFM 11.07%
ROA(3y)-11.48%
ROA(5y)-6.86%
ROE(3y)-13.03%
ROE(5y)-7.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y0.71%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.3
Debt/EBITDA 0.83
Cap/Depr 182.54%
Cap/Sales 7.87%
Interest Coverage N/A
Cash Conversion 476.07%
Profit Quality 568.48%
Current Ratio 7.78
Quick Ratio 7.64
Altman-Z 6.62
F-Score7
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)88.65%
Cap/Depr(5y)309.03%
Cap/Sales(3y)4.67%
Cap/Sales(5y)4.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)107.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130.77%
EPS Next Y118.71%
EPS Next 2Y7.28%
EPS Next 3Y10.01%
EPS Next 5Y13.9%
Revenue 1Y (TTM)62.43%
Revenue growth 3Y51.99%
Revenue growth 5Y57.33%
Sales Q2Q%39.5%
Revenue Next Year55.38%
Revenue Next 2Y14.04%
Revenue Next 3Y12.7%
Revenue Next 5Y11.77%
EBIT growth 1Y98.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year190.19%
EBIT Next 3Y33.72%
EBIT Next 5Y13.1%
FCF growth 1Y179.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y253.71%
OCF growth 3YN/A
OCF growth 5YN/A